

# European Biosimilar Market to Reach US\$ 25,446 Million by 2027 | Industry CAGR of 22.8%

SHERIDAN, WY, UNITED STATES, December 1, 2022 /EINPresswire.com/ -- According to the latest report by IMARC Group, titled "European Biosimilar Market: Opportunities, Challenges, Risks, and Opportunities, 2022-2027", the [European biosimilar market in Europe reached a value of US\\$ 6,735 Million](https://www.imarcgroup.com/europe-biosimilar-market/requestsamplerequestsample) in 2021. Looking forward, IMARC Group expects the market to reach US\$ 25,446 million by 2027, exhibiting at a CAGR of 22.8% during 2022-2027.



European Biosimilar Market:

Biosimilars, also called subsequent entry biologics (SEBs), refer to medical products that are similar to reference biologics in terms of their quality, efficacy, safety, etc. They are generally produced from living organisms, including yeast, animal or plant cells, bacteria, etc., and have a complex molecular structure. In addition to this, biosimilars are manufactured under the guidance of licensed facilities that are considered as an essential part of post-market surveillance. As such, they are extensively utilized in the production of therapeutic proteins, vaccines, monoclonal antibodies, etc.

Key: The report provides a comprehensive analysis of the European biosimilar market, covering the market size, growth, and forecast. It also provides a detailed analysis of the market structure, including the market segmentation, competitive landscape, and key players. The report also provides a detailed analysis of the market drivers, challenges, and opportunities.

For more information, please visit the IMARC Group website:

<https://www.imarcgroup.com/europe-biosimilar-market/requestsamplerequestsample>

European Biosimilar Market:

The growing investments in the field of medical science and biotechnology are primarily driving the Europe biosimilar market. Moreover, the expanding geriatric population and the increasing prevalence of autoimmune diseases, cancer, diabetes, etc., owing to the sedentary lifestyle patterns of individuals, are also positively influencing the regional market. Apart from this, the launch of numerous favorable policies by government bodies and third-party payers in Europe to upgrade the existing healthcare infrastructures and the patent expiration of various blockbuster biologics are acting as significant growth-inducing factors. Furthermore, the development of state-of-the-art technology for comparing the characteristics, including chemical identity, purity, bioactivity, etc., of the proposed biosimilars to their reference product is stimulating the market growth. Besides this, the inflating need for safe and affordable alternatives to originator biological therapies is projected to fuel the Europe biosimilar market in the coming years.

Novartis, Pfizer, Teva, Celltrion, Samsung Bioepis, Amgen, Apotex, Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord Healthcare Ltd, Boehringer Ingelheim, Hexal Ag, Stada Arzneimittel Ag

Novartis, Pfizer, Teva, Celltrion, Samsung Bioepis, Amgen, Apotex, Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord Healthcare Ltd, Boehringer Ingelheim, Hexal Ag, Stada Arzneimittel Ag

Novartis, Pfizer, Teva, Celltrion, Samsung Bioepis, Amgen, Apotex, Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord Healthcare Ltd, Boehringer Ingelheim, Hexal Ag, Stada Arzneimittel Ag

- Novartis
- Pfizer
- Teva
- Celltrion
- Samsung Bioepis
- Amgen
- Apotex
- Ratiopharm
- Mylan
- Merck Sharp & Dohme
- Eli Lilly
- Accord Healthcare Ltd
- Boehringer Ingelheim
- Hexal Ag
- Stada Arzneimittel Ag

Novartis, Pfizer, Teva, Celltrion, Samsung Bioepis, Amgen, Apotex, Ratiopharm, Mylan, Merck Sharp & Dohme, Eli Lilly, Accord Healthcare Ltd, Boehringer Ingelheim, Hexal Ag, Stada Arzneimittel Ag

- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab

Follitropin Alfa  
Adalimumab

□□□□□□ □□□□□□□□ □□ □□□□□□□□□□

Auto-Immune Diseases  
Blood Disorder  
Diabetes  
Oncology  
Growth Deficiency  
Female Infertility

□□□□□□ □□□□□□□□ □□ □□□□□□□□□□□□□□ □□□□

In-house Manufacturing  
Contract Manufacturing

□□□□□□□□ □□ □□□□□□□□:

Italy  
Germany  
United Kingdom  
France  
Spain  
Others

Ask Analyst for 10% free customized report: <https://www.imarcgroup.com/europe-biosimilar-market>

□□□□: We are updating our reports, If you want the report with the latest primary and secondary data (□□□□-□□□□) including industry trends, market size and Competitive landscape, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.

□□□□ □□□□□□□□□□□□ □□ □□□□ □□□□□□□□:

□□□□□□□□ □□□□□□□□□□□□ (□□□□-□□□□)  
□□□□□□□□ □□□□□□□□ (□□□□-□□□□)

Market Trends  
Market Drivers and Success Factors  
Impact of COVID-19  
Value Chain Analysis  
Comprehensive mapping of the competitive landscape

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Elena Anderson  
IMARC Services Private Limited  
+ 16317911145  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/604123468>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.